Figure 3.

Influence of biologic DMARDs on cf-nDNA levels. cf-nDNA released from fibroblast-like synoviocytes (FLS) treated with or without tocilizumab (TCZ) (A) or etanercept (ETN) (B), and with TNF-α or IL-6/IL6R. Results are mean ± SEM (Student’s t-test), n = 5; *P < 0.05; ns: not significant. cf-nDNA levels in plasma of RA patients incubated with (C) TCZ or ETN, or (D) adalimumab (ADA), certolizumab (CZP), or golimumab (GLM). (E) cf-nDNA levels in plasma of RA patients incubated with TCZ, ADA, or GLM after 60 min. Results are mean ± SEM (Wilcoxon signed-rank test); n = 7; *P < 0.05, **P < 0.01; ns: not significant